Merck (MRK) Assets (2009 - 2026)
Merck (MRK) reported Assets of $128.7 billion for Q1 2026, up 11.78% year-over-year from $115.1 billion in Q1 2025, and down 5.98% quarter-over-quarter from $136.9 billion in Q4 2025.
Merck (MRK) Assets (2009 - 2026) Analysis & Trends
Merck (MRK) has 18 years of Assets data on file, last reported at $128.7 billion in Q1 2026.
- Assets for Q1 2026 came in at $128.7 billion, up 11.78% year-over-year; the trailing twelve-month figure through Mar 2026 was $128.7 billion (up 11.78% YoY), and the FY2025 annual result was $136.9 billion, up 16.87% from the prior year.
- Assets eased to $128.7 billion in Q1 2026 per MRK's latest filing, from $136.9 billion in the prior quarter.
- Over five years, Assets peaked at $136.9 billion in Q4 2025 and troughed at $104.5 billion in Q2 2023.
- A 5-year average of $113.9 billion and a median of $109.2 billion in 2022 frame the typical range for Assets.
- The sharpest annual moves came in 2022 and 2023: Assets advanced 18.09% in 2022, then retreated 2.45% in 2023.
- A 5-year view of Assets shows it stood at $109.2 billion in 2022, then retreated by 2.28% to $106.7 billion in 2023, then gained by 9.78% to $117.1 billion in 2024, then gained by 16.87% to $136.9 billion in 2025, then decreased by 5.98% to $128.7 billion in 2026.
- Business Quant data shows MRK's Assets at $128.7 billion in Q1 2026, $136.9 billion in Q4 2025, and $129.5 billion in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 96,436,181.12 Bn | 96,436,176.16 Bn | 7.76 Bn | 84.76 Bn |
| 2 | Eli Lilly | 1,017.30 Bn | 1,012.01 Bn | 16.22 Bn | 116.58 Bn |
| 3 | Johnson & Johnson | 579.61 Bn | 557.55 Bn | 15.96 Bn | 200.89 Bn |
| 4 | AbbVie | 402.30 Bn | 392.96 Bn | 10.78 Bn | 136.46 Bn |
| 5 | Merck | 294.24 Bn | 288.59 Bn | 12.09 Bn | 128.69 Bn |
| 6 | Amgen | 191.82 Bn | 179.78 Bn | 5.87 Bn | 92.50 Bn |
| 7 | Gilead Sciences | 155.93 Bn | 148.21 Bn | 5.52 Bn | 56.28 Bn |
| 8 | Pfizer | 149.05 Bn | 136.28 Bn | -1.21 Bn | 208.00 Bn |
| 9 | Bristol Myers Squibb | 116.33 Bn | 105.88 Bn | 8.07 Bn | 86.48 Bn |
| 10 | Novartis Ag | 112.59 Bn | 111.90 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 128.69 Bn |
| Dec 31, 2025 | 136.87 Bn |
| Sep 30, 2025 | 129.55 Bn |
| Jun 30, 2025 | 117.52 Bn |
| Mar 31, 2025 | 115.12 Bn |
| Dec 31, 2024 | 117.11 Bn |
| Sep 30, 2024 | 117.53 Bn |
| Jun 30, 2024 | 112.63 Bn |
| Mar 31, 2024 | 105.85 Bn |
| Dec 31, 2023 | 106.68 Bn |
| Sep 30, 2023 | 106.73 Bn |
| Jun 30, 2023 | 104.47 Bn |
| Mar 31, 2023 | 107.80 Bn |
| Dec 31, 2022 | 109.16 Bn |
| Sep 30, 2022 | 107.08 Bn |
| Jun 30, 2022 | 107.10 Bn |
| Mar 31, 2022 | 106.67 Bn |
| Dec 31, 2021 | 105.69 Bn |
| Sep 30, 2021 | 93.49 Bn |
| Jun 30, 2021 | 90.69 Bn |